(Ala11.22.28)-VIP (human, mouse, rat), a highly selective human VPAC1 receptor agonist, shows a 1000-fold higher efficiency in stimulating adenylate cyclase activity from VPAC1 than VPAC2 receptors. It is a valid pharmacological tool for characterizing VPAC1 receptor-mediated events.